Source link : https://www.newshealth.biz/health-news/promising-phase-3-data-on-dmd-hopeful-givinostat/
When added to corticosteroids, treatment with the investigational agent givinostat led to statistically and clinical meaningful benefits in ambulatory children with Duchenne muscular dystrophy (DMD) compared with placebo, including reduced decline of muscle function and strength, results from the phase 3 EPIDYS trial show. Although results in the four-stair climb assessment from baseline to 72 […]
Author : News Health
Publish date : 2024-03-20 21:34:01
Copyright for syndicated content belongs to the linked Source.